Browsing by Author "Duarte, P"

Now showing 1 - 3 of 3

Patients Age 40 Years and Younger with Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence from Latin America
(Lippincott Williams and Wilkins, 2023) Martinez-Cordero, H; Peña, C; Schutz, NP; Bove, V; Villano, F; Beltran, C; Donoso, J; Lopez-Vidal, H; Roa-Salinas, MA; Soto, P; Ochoa, P; Duarte, P; Remaggi, G; Corzo, A; Shanley, C; Lopresti, S; Orlando, S; Verri, V; Quiroga, LD; Fantl, D; Ramirez, J; Ospina-Idarraga, A; Idrobo, H; Quintero, G; Gomez, R; Cantu-Martinez, O; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Galvez-Cardenas, KM; Salazar, LA; Novoa-Caicedo, I; Fuentes-Lacouture, MC; Spirko, P; Arbelaez, MI; Pereira, M; Valdes, J; Vasquez, J; Von-Glasenapp, A; Riva, E
PURPOSEMultiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.PATIENTS AND METHODSWe analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.RESULTSThere were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival.CONCLUSIONIn conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly. © American Society of Clinical Oncology.
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
(Taylor and Francis Ltd., 2023) Peña, C; Riva, E; Schutz, N; Ramírez, A; Vásquez, J; del-Carpio, D; Seehaus, C; Ochoa, P; Vengoa, R; Duarte, P; Martínez-Cordero, H; Figueredo, Y; Ríos, RO; Ramírez, J; Bove, V; Roa, M; Russo, M; Espinoza, M; Rodriguez, G; Remaggi, G; Enciso, ME; Chandía, M; Fantl, D.
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis of pPCL between 2012 and 2020 were included. 72 patients were included. Treatment was based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets in 38% and chemotherapy plus IMIDs and/or PI in 29%. The mortality rate at 3 months was 30%. The median overall survival (OS) was 18 months. In the multivariate analysis, frontline PI-based triplets, chemotherapy plus IMIDs and/or PI therapy, and maintenance were independent factors of better OS. In conclusion, the OS of pPCL is still poor in LATAM, with high early mortality. PI triplets, chemotherapy plus IMIDs, and/or PI and maintenance therapy were associated with improved survival. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
The Latin-American Experience in POEMS Syndrome: A Study of the GELAMM (Grupo de Estudio Latinoamericano de Mieloma Múltiple)
(S. Karger AG, 2024) Gallardo-Pérez, MM; Negrete-Rodríguez, P; Gertz, MA; Peña, C; Riva, E; Gilli, V; Rodríguez, G; Samánez, C; Ferreira, J; Portiño, S; Montaña, J; León, P; Gutiérrez, Y; Del-Castanhel, C; Seehaus, C; Funes, ME; Meneces-Bustillo, R; Duarte, P; Shanley, C; Elvira, G; Ochoa, P; López-Vidal, H; Martinez-Cordero, H; Vasquez, J; Von-Glasenapp, A; Donoso, J; Viñuela, JL; Ruiz-Delgado, GJ; Ruiz-Argüelles, GJ
Introduction: POEMS syndrome is a rare paraneoplastic syndrome caused by an underlying plasma cell disorder. The acronym refers to the following features: polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal paraproteinemia, and skin changes. Methods: The study was conducted at 24 hematological centers across 8 Latin-American countries. The study included a total of 46 patients {median age was 52 years (interquartile range [IQR]: 42 61.5), 30 males and 16 females} fulfilling the POEMS syndrome criteria diagnosed over a period of 12 years (January 1, 2011, through July 31, 2023). Epidemiological and clinical data were collected in an ad hoc database sent to the members of GELAMM, as well as the Kolmogorov-Smirnov test and Kaplan-Meier estimates. Results: All patients had polyneuropathy and monoclonal gammopathy; 89% had bone marrow plasma cell infiltration, 33% had sclerotic bone lesions. Only 10 patients underwent vascular endothelial growth factor (VEGF) testing in plasma samples. The paraproteinemia was IgG λ in 32% and IgA λ in 30%. 59% patients presented with cutaneous changes, mainly hyperpigmentation, 54% had organomegaly, and 74% endocrinopathy. The median interval from symptom onset to diagnosis was 7.7 months (IQR: 4.0 12.6). 69% of patients received a single line of treatment. The median follow-up period was 25 months (IQR: 9.37 52.0) and the 2-year overall survival rate was 100%. All patients who underwent transplantation (43%) are alive, with a median follow-up of 45.62 months (IQR: 15.46 70). Conclusion: This study investigates POEMS syndrome in Latin America and presents an initial overview of the disease in the region. VEGF usage is recommended for accurate diagnosis, but only 7 hematology centers in the region used it. Survival rate in Latin America is comparable with those observed internationally.